First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC is a research paper published in New England Journal of Medicine (2023). On theSindex it has a DataRank of 4.6. It has been cited 218 times, with 100 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.808
From this paper's citation signal
Citation Network Contribution
3.8
From 100 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 100 citers.
NCI NIH HHS
Grant: P30CA008748
NCI NIH HHS
Grant: R25 CA233208
NIH HHS
Grant: 1R01CA251591001A1
NIH HHS
Grant: 1R01CA273224-01
Integration of Imaging and Circulating Plasma Cell-Free DNA Sequencing Using MSK-ACCESS to Monitor Treatment Response and Predict Progression in Patients With Multiple Cancers on Targeted Therapy
NCI NIH HHS
Grant: R01 CA251591
Loxo Oncology, a wholly owned subsidiary of Eli Lilly
Grant: N/A
NCI NIH HHS
Grant: R01 CA273224
FWCI
25.98
Citation Percentile
1.0%
Influential Citations
24
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data
Additional file 1 of Response to immune checkpoint inhibitor combination therapy in metastatic RET-mutated lung cancer from real-world retrospective data